Anixa Biosciences
ANIX
41 hedge funds and large institutions have $9.05M invested in Anixa Biosciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 7 closing their positions.
1,460% more call options, than puts
Call options by funds: $78K | Put options by funds: $5K
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
0.52% less ownership
Funds ownership: 11.48% → 10.96% (-0.52%)
2% less funds holding
Funds holding: 42 → 41 (-1)
11% less capital invested
Capital invested by funds: $10.2M → $9.05M (-$1.16M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$277K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$47.1K |
| 3 |
KeyBank National Association
Cleveland,
Ohio
|
+$45.5K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$38.9K |
| 5 |
Morgan Stanley
New York
|
+$36.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$311K |
| 2 |
Two Sigma Advisers
New York
|
-$110K |
| 3 |
Two Sigma Investments
New York
|
-$108K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$101K |
| 5 |
VF
Virtu Financial
New York
|
-$84K |
ANIX Hedge Fund Activity: Q1 2022 in Review
41 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2022, worth a combined $9.05M — down 11% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ANIX and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 12 added.
The largest buyer was Long Focus Capital Management, adding an estimated $277K. The largest seller was Renaissance Technologies, cutting an estimated $311K.
- 41 institutional investors held Anixa Biosciences (ANIX) as of Q1 2022, down from 42 in Q4 2021.
- Funds reported $9.05M of Anixa Biosciences stock for Q1 2022, down 11% quarter-over-quarter.
- 6 funds opened new Anixa Biosciences positions in Q1 2022 and 7 closed out, a net change of -1 holder.
- The largest Anixa Biosciences buyer in Q1 2022 was Long Focus Capital Management, an estimated $277K added.
- The largest Anixa Biosciences seller in Q1 2022 was Renaissance Technologies, an estimated $311K sold.
Based on aggregated 13F filings for Q1 2022.